FDA and the Harmful Side Effect (Risk Aversion): Will Congressional Cures Be Worse Than the Disease? Category: Miscellany cGxP's FDA and Regulatory Issues The Pharma Industry Submitted by pharmamanufacturing on Thu, 02/15/2007 - 01:31 In a two-part op-ed, Dr. Henry Miller of the Hoover Institute looks at FDA and asks two critical questions: Can the Agency undo the paralyzing effects of decades of risk averse regulation? What impact could the new bills now being discussed in Congress have? The article's thought provoking, whatever your political leanings. Stay tuned to March's issue of Pharmaceutical Manufacturing, for a cover story on FDA.